Correction: AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models

In “AAV-mediated gene therapy for Choroideremia: Preclinical studies in personalized in vitro models”, by Vasireddy et al (DOI: 10.1371/journal.pone.0061396), two panels in Fig 1 contained immunoblot images that were spliced together by the authors for the sake of re-ordering lanes and omitting unnecessary data on the published figure. The authors apologize for not acknowledging these manipulations in figure preparation in the original Figure legend.

In the corrected version of Fig 1, we present the same data as those published in the original article. However, panels (IIi) and (III) have been modified so that black, vertical lines clearly indicate where lanes have been spliced together during figure preparation. To demonstrate the validity of the data in the affected panels, we present the original gel images in Supporting Figs 1 and 2. The figure legends clearly indicate which lanes from the original gels are included in the published figure. See the original article for detailed Methods and a discussion of the Results. We have also replicated the Fig 1 immunoblot experiments in full (including the transfections and lysate preparations) but placed the samples in the correct order in the new gels. Those unmanipulated blot images are presented as Fig 2 of this Correction.

thumbnail

Download:

*

PPT

PowerPoint slide

*

PNG

larger image

*

TIFF

original image

Fig 1. Generation and Characterization of AAV2.

hCHM. I). Schematic of the AAV proviral plasmid carrying human CHM. under the control of the cytomegalovirus enhancer chicken beta actin (eCBA) promoter. ITR: Inverted terminal repeats; Ori: Replication origin; KanR: Kanamycin resistance gene. II) i) Immunoblot and ii) fluorescent analysis reveals REP-1 protein in CHO cells transfected with pAAV2.hCHM. Lane A: Transfected cell (25 μg protein), B: Control (untransfected) cells, C- protein marker. Immunocytochemical analysis revealed the localization of REP-1 to the cytosolic region (II-ii-B; Green). No REP1 is observed in control cells (II-ii-A). Nuclei are stained with DAPI and appear blue. Scale bar is 50 μM. III) Immunoblot analysis of CHO cells infected with 1E3-2E5 viral genomes (vg) of AAV2. hCHM shows an increase in REP-1 protein (indicated by arrow) proportional to the titer. Positive (+ve) control: pAAV2. hCHM-transfected CHO cell lysate. Black lines in panels IIi and III indicate where lanes from original immunoblots have been spliced together during figure preparation (original legend is reproduced from the

References

1. Vasireddy V, Mills JA, Gaddameedi R, Basner-Tschakarjan E, Kohnke M, Black AD, et al. (2013) AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized Models. PLoS ONE 8(5): e61396. pmid:23667438